PSP currently exhibits growing pipeline 14 drug candidates.
PSP therapeutics pipeline in 2017
The study analyzed that PSP therapeutics pipeline comprises approximately 14 drug candidates in different stages of development. The exact cause of PSP is unknown, but it has been observed that PSP is the accumulation of abnormal deposits of the tau protein in nerve cells in the brain, and eventual toxicity in nerve cells in the brain stem. The appearance of deposits of the microtubule-associated tau protein termed ‘neurofibrillary tangles’ is a common feature of tauopathies and development of progressive supranuclear palsy.
Access Report Summary with Detailed TOC on “Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/psp-pipeline-analysis
Insights on pipeline segments
According to the research findings, most of the drug candidates in PSP therapeutics pipeline are being developed as small molecule agents. Also, majority of the pipeline drug candidates are being developed using the oral route of administration.
Maximum drugs being developed as small molecule
Many companies are more focused on developing their drug candidate’s as small molecule, since small molecule can easily pass through the blood brain barrier due to their low molecular weight and small size.
Various collaborations taking place for PSP drug development
In April 2017, Biogen Inc. entered into an exclusive worldwide license agreement with Bristol-Myers Squibb Company to develop and commercialize BMS-986168, a Phase II investigational medicine for the treatment of Alzheimer’s disease (AD) and PSP. Some of the key players developing drugs for the treatment of progressive supranuclear palsy include AbbVie Inc., Biogen Inc., Asceneuron SA, Alzprotect SAS and others.
PSP Therapeutics Pipeline Analysis